|Day Low/High||200.81 / 204.12|
|52 Wk Low/High||166.30 / 211.90|
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.
Let's check out the charts to get a sense of where prices could be headed.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Gains in Amgen, CVS, and others helped offset declines in other stocks, as the RMPIA rose over the last two months to 0.6%, handily beating all the major domestic stock market averages.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
In the short run the stock of this biotech giant could bounce as momentum has slowed, but the bigger picture is for further weakness.
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
RMPIA outperformed once gain during April.
Plus a possible setup in Amgen as earnings approach.
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
In this day and age, companies must be 'disruptors' or get left in the dust.
The RMPIA rose 10.5% during the first half of the current quarter.
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.